Literature DB >> 28344319

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

V Atsaves1, N Tsesmetzis1, D Chioureas1, L Kis1,2, V Leventaki3, E Drakos4, T Panaretakis1, D Grander1, L J Medeiros5, K H Young5, G Z Rassidakis1,2,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28344319     DOI： 10.1038/leu.2017.103

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.

Authors:  Konstantinos Georgiou; Longyun Chen; Mattias Berglund; Weicheng Ren; Noel F C C de Miranda; Susana Lisboa; Marco Fangazio; Shida Zhu; Yong Hou; Kui Wu; Wenfeng Fang; Xianhuo Wang; Bin Meng; Li Zhang; Yixin Zeng; Govind Bhagat; Magnus Nordenskjöld; Christer Sundström; Gunilla Enblad; Riccardo Dalla-Favera; Huilai Zhang; Manuel R Teixeira; Laura Pasqualucci; Roujun Peng; Qiang Pan-Hammarström
Journal:  Blood       Date:  2016-03-30       Impact factor: 22.113

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

4.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

5.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

6.  Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.

Authors:  Joseph D Khoury; L Jeffrey Medeiros; George Z Rassidakis; Marwan A Yared; Panagiota Tsioli; Vasiliki Leventaki; Annette Schmitt-Graeff; Marco Herling; Hesham M Amin; Raymond Lai
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors:  Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

8.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

Review 9.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

10.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728
View more
  75 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

2.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

3.  A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.

Authors:  Jing-Ping Zhang; Zhihui Song; Hong-Bo Wang; Lang Lang; Yuan-Zhong Yang; Wenming Xiao; Daniel E Webster; Wei Wei; Stefan K Barta; Marshall E Kadin; Louis M Staudt; Masao Nakagawa; Yibin Yang
Journal:  Blood       Date:  2019-05-31       Impact factor: 22.113

4.  Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.

Authors:  Daniel J Landsburg; Alexa Koike; Sunita D Nasta; Jakub Svoboda; Stephen J Schuster; Mariusz A Wasik; Gabriel C Caponetti
Journal:  Cancer Immunol Immunother       Date:  2020-08-28       Impact factor: 6.968

Review 5.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

Review 6.  Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Authors:  Lorenzo Falchi
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

7.  Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors.

Authors:  Sahyun Pak; Wansuk Kim; Yunlim Kim; Cheryn Song; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-10       Impact factor: 4.553

8.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Authors:  Tammy Linlin Song; Maarja-Liisa Nairismägi; Yurike Laurensia; Jing-Quan Lim; Jing Tan; Zhi-Mei Li; Wan-Lu Pang; Atish Kizhakeyil; Giovani-Claresta Wijaya; Da-Chuan Huang; Sanjanaa Nagarajan; Burton Kuan-Hui Chia; Daryl Cheah; Yan-Hui Liu; Fen Zhang; Hui-Lan Rao; Tiffany Tang; Esther Kam-Yin Wong; Jin-Xin Bei; Jabed Iqbal; Nicholas-Francis Grigoropoulos; Siok-Bian Ng; Wee-Joo Chng; Bin-Tean Teh; Soo-Yong Tan; Navin Kumar Verma; Hao Fan; Soon-Thye Lim; Choon-Kiat Ong
Journal:  Blood       Date:  2018-07-27       Impact factor: 22.113

Review 9.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807

10.  Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

Authors:  Cuiling Zhou; Gang Che; Xiaobin Zheng; Junlan Qiu; Zhinan Xie; Yunyan Cong; Xiaofeng Pei; Hongyu Zhang; Huanhuan Sun; Haiqing Ma
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-20       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.